company background image
ALINT logo

IntegraGen ENXTPA:ALINT Stock Report

Last Price

€0.60

Market Cap

€3.9m

7D

2.5%

1Y

-17.1%

Updated

30 Jan, 2025

Data

Company Financials

ALINT Stock Overview

Provides researchers with sequencing solutions, data management tools, and biostatistical, and bioinformatics support services in France. More details

ALINT fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

IntegraGen SA Competitors

Price History & Performance

Summary of share price highs, lows and changes for IntegraGen
Historical stock prices
Current Share Price€0.60
52 Week High€0.93
52 Week Low€0.43
Beta0.15
1 Month Change7.08%
3 Month Change18.63%
1 Year Change-17.12%
3 Year Change-50.41%
5 Year Change-58.13%
Change since IPO-93.34%

Recent News & Updates

Why Investors Shouldn't Be Surprised By IntegraGen SA's (EPA:ALINT) Low P/S

Dec 14
Why Investors Shouldn't Be Surprised By IntegraGen SA's (EPA:ALINT) Low P/S

Lacklustre Performance Is Driving IntegraGen SA's (EPA:ALINT) Low P/S

Aug 28
Lacklustre Performance Is Driving IntegraGen SA's (EPA:ALINT) Low P/S

Recent updates

Why Investors Shouldn't Be Surprised By IntegraGen SA's (EPA:ALINT) Low P/S

Dec 14
Why Investors Shouldn't Be Surprised By IntegraGen SA's (EPA:ALINT) Low P/S

Lacklustre Performance Is Driving IntegraGen SA's (EPA:ALINT) Low P/S

Aug 28
Lacklustre Performance Is Driving IntegraGen SA's (EPA:ALINT) Low P/S

There's No Escaping IntegraGen SA's (EPA:ALINT) Muted Revenues

Feb 17
There's No Escaping IntegraGen SA's (EPA:ALINT) Muted Revenues

Pinning Down IntegraGen SA's (EPA:ALINT) P/E Is Difficult Right Now

Apr 19
Pinning Down IntegraGen SA's (EPA:ALINT) P/E Is Difficult Right Now

Shareholder Returns

ALINTFR BiotechsFR Market
7D2.5%2.5%0.9%
1Y-17.1%-29.1%3.4%

Return vs Industry: ALINT exceeded the French Biotechs industry which returned -29.2% over the past year.

Return vs Market: ALINT underperformed the French Market which returned 1.7% over the past year.

Price Volatility

Is ALINT's price volatile compared to industry and market?
ALINT volatility
ALINT Average Weekly Movement11.4%
Biotechs Industry Average Movement7.5%
Market Average Movement4.5%
10% most volatile stocks in FR Market9.9%
10% least volatile stocks in FR Market2.4%

Stable Share Price: ALINT's share price has been volatile over the past 3 months compared to the French market.

Volatility Over Time: ALINT's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of French stocks.

About the Company

FoundedEmployeesCEOWebsite
200044Bernard Courtieuintegragen.com

IntegraGen SA provides researchers with sequencing solutions, data management tools, and biostatistical, and bioinformatics support services in France. The company’s genomic pharma services DNA sequencing for oncology and rare disease research; and NGS testing for cancer research. It also provides MERCURY, an online biological interpretation tool for oncology intended to assist pathologists and oncologists in transforming raw data obtained through high-throughput sequencing into a molecular report for translational and clinical research use; Galileo, a cloud-based app for dynamic exporation of RNA-Seq expression data; and GeCo, a genomic consulting service that offers researchers with access to biostatistics and bioanalytics experts.

IntegraGen SA Fundamentals Summary

How do IntegraGen's earnings and revenue compare to its market cap?
ALINT fundamental statistics
Market cap€3.94m
Earnings (TTM)-€24.71k
Revenue (TTM)€11.08m

0.4x

P/S Ratio

-162.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALINT income statement (TTM)
Revenue€11.08m
Cost of Revenue€6.74m
Gross Profit€4.34m
Other Expenses€4.36m
Earnings-€24.71k

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.0037
Gross Margin39.16%
Net Profit Margin-0.22%
Debt/Equity Ratio45.8%

How did ALINT perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/30 04:19
End of Day Share Price 2025/01/30 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

IntegraGen SA is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Thomas GuillotKepler Cheuvreux
Arnaud GuérinPortzamparc BNP Paribas